Impact of troponin I-autoantibodies in chronic dilated and ischemic cardiomyopathy

• Verfasst von: Dösch, Andreas [VerfasserIn]
• Verfasst von: Mueller, Susanne [VerfasserIn]
• Verfasst von: Nelles, Manfred [VerfasserIn]
• Verfasst von: Konstandin, Mathias [VerfasserIn]
• Verfasst von: Celik, Sultan [VerfasserIn]
• Verfasst von: Frankenstein, Lutz [VerfasserIn]
• Verfasst von: Goeser, Stefan [VerfasserIn]
• Verfasst von: Kaya, Ziya [VerfasserIn]
• Verfasst von: Koch, Achim [VerfasserIn]
• Verfasst von: Zugck, Christian [VerfasserIn]
• Verfasst von: Katus, Hugo [VerfasserIn]
• Titel: Impact of troponin I-autoantibodies in chronic dilated and ischemic cardiomyopathy
• Verf.angabe: Andreas O. Doesch, Susanne Mueller, Manfred Nelles, Mathias Konstandin, Sultan Celik, Lutz Frankenstein, Stefan Goeser, Ziya Kaya, Achim Koch, Christian Zugck, Hugo A. Katus
• Jahr: 2011
• Umfang: 11 S.
• Fussnoten: Published online: 20 October 2010 ; Gesehen am 14.06.2022
• Titel Quelle: Enthalten in: Basic research in cardiology
• Ort Quelle: [Darmstadt u.a.] : Steinkopff, 1937
• Jahr Quelle: 2011
• Band/Heft Quelle: 106(2011), Seite 25-35
• ISSN Quelle: 1435-1803
• DOI: doi:10.1007/s00395-010-0126-z
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Dilated cardiomyopathy
• Sach-SW: Extracorporeal immunoadsorption
• Sach-SW: Ischemic cardiomyopathy
• Sach-SW: Outcome
• Sach-SW: Troponin I autoantibodies
• K10plus-PPN: 1806975378

Abstract

The aim of this study was to investigate the prognostic value of circulating troponin I (TNI)-autoantibodies in plasma of patients with chronic heart failure. Sera of 390 heart failure patients were tested for the presence of anti-TNI antibodies by enzyme-linked immunosorbent assay (ELISA), including 249 (63.8% of total) patients with dilated cardiomyopathy (DCM) and 141 (36.2% of total) patients with ischemic cardiomyopathy (ICM). A total of 72 patients (18.5% of total) were female and 318 (81.5% of total) were male. Mean patient age was 54.6 ± 11.3 years and mean follow-up time was 3.8 ± 3.2 years. TNI-autoantibodies (titer of ≥1:40) were detected in 73 out of 390 patients (18.7% of total). In TNI-autoantibody positive patients mean left ventricular ejection fraction (LVEF) was 27.6 ± 5.8%, compared to 25.8 ± 5.9% in TNI-autoantibody negative patients, P = 0.03. The combined end-point of death (n = 118, 30.3% of total) or heart transplantation (HTX) (n = 44, 11.3% of total) was reached in 162 patients (41.5% of total). Kaplan-Meier analysis demonstrated superior survival (combined end-point of death or HTX) in patients with DCM versus ICM (P = 0.0198) and TNI-autoantibody positive patients versus TNI-autoantibody negative patients (P = 0.0348). Further subgroup analysis revealed a favorable outcome in TNI-positive patients with heart failure if the patients suffered from DCM (P = 0.0334), whereas TNI-autoantibody status in patients with ICM was not associated with survival (P = 0.8486). In subsequent multivariate Weibull-analysis, a positive TNI serostatus was associated with a significantly lower all-cause mortality in DCM patients (P = 0.0492). The presence of TNI-autoantibodies in plasma is associated with an improved survival in patients with chronic DCM, but not ICM. This might possibly indicate a prophylactic effect of TNI-autoantibodies in this subgroup of patients, encouraging further studies into possible protective effects of antibodies against certain cardiac target structures.